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Abstract
β-arrestins are versatile adaptor proteins that play a vital role in regulation of G
protein coupled receptor (GPCR) trafficking and signalling properties. PDZ
proteins have previously been shown to modulate β-arrestin2 recruitment and
receptor internalization for many GPCRs including Corticotropin-Releasing Factor
Receptor 1 (CRFR1), a receptor whose antagonists have been shown to
demonstrate both anxiolytic- and antidepressant-like effects. Further
characterization of the interplay between β-arrestins and PDZ proteins may aid in
determining a potential mechanism for PDZ protein regulation of GPCR
trafficking. Our findings suggest that PDZ proteins PSD-95, MAGI1, and PDZK1
complex with β-arrestin2 by interacting via the PDZ domain. Using a proteomic
approach, mutational analyses were used to reveal that the β-arrestin2 A175F
mutant impairs interaction with PSD-95. Additionally, this mutant form of βarrestin2 shows decreased CRF-stimulated recruitment to CRFR1. Thus,
investigating how β-arrestins and PDZ proteins interact could provide further
insight into GPCR trafficking properties and the development of novel
therapeutics.

Key Words: G protein-coupled receptors, CRFR1, β-arrestins, PDZ, PSD-95, MAGI1,
PDZK1, endocytosis, trafficking, mental disorders, anxiety, depression
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Chapter 1: Introduction
1.1 G Protein-Coupled Receptors
G protein-coupled receptors (GPCRs) constitute the single largest and most
diverse class of transmembrane receptor proteins encoded by the mammalian genome
(Oldham & Hamm, 2008). Structural features common to all GPCRs include seven
transmembrane helical domains, an extracellular N terminus, and an intracellular C
terminus (Kobilka, 2007). GPCRs can be activated upon binding of a wide variety of
ligands including peptides, hormones, amino acids, neurotransmitters, odorants and
photons, among others (Kroeze et al., 2003). Activation of GPCRs by an agonist leads to
a conformational change in the α-subunit of the heterotrimeric G protein such that it
dissociates from the Gβγ subunit. This is caused by cycling of the α-subunit between an
inactive GDP-bound state and an active GTP-bound conformation that can then regulate
various aspects of downstream signaling pathways (Oldham & Hamm, 2008). Each
GPCR can be bound by multiple ligands that can induce activation of a specific signaling
pathway.
GPCRs regulate a myriad of physiological processes and are heterogeneously
distributed in many different tissues (Tautermann, 2014). This versatility, coupled with
the convenience of being able to manipulate an entire intracellular signaling cascade with
a single target, makes GPCRs excellent pharmaceutical targets. This is of particular
importance when considering nearly 40% of all current drugs in clinical use target
GPCRs, thus marking their importance for the development of novel therapeutics
(Tautermann, 2014).
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1.1.2 GPCR interacting Proteins
GPCRs can interact with numerous proteins that function not only to attenuate
their signalling, but also to couple these receptors to heterotrimeric G-proteinindependent signalling pathways (Magalhaes et al., 2012). In addition, intracellular and
transmembrane proteins associate with GPCRs and regulate their processing in the
endoplasmic reticulum, trafficking to the cell surface, compartmentalization to plasma
membrane microdomains, endocytosis and trafficking between intracellular membrane
compartments (Magalhaes et al., 2012). Examples of proteins that can bind to GPCRs
include β-arrestin, receptor activity-modifying proteins (RAMPS), regulators of Gprotein signalling (RGS), GPCR-associated sorting proteins (GASPs), Homer proteins,
small GTPases, PDZ domains, spinophilin, protein phosphatases, calmodulin, optineurin
and Src homology 3 (SH3) containing proteins (Magalhaes et al., 2012).

1.2 Arrestins
Arrestins are a predominantly cytoplasmic and versatile family of proteins. In
mammals, the family consists of four members: arrestin 1 (visual or rod arrestin), arrestin
2 (β-arrestin1), arrestin 3 (β-arrestin2), and arrestin 4 (cone or X-arrestin) (Han et al.,
2001). Arrestin 1 and arrestin 4 are exclusively expressed in the visual system, either in
rod or cone cells. Conversely, β-arrestin1 and β-arrestin2 are ubiquitously expressed in
virtually all cell types and within a variety of tissues (Han et al., 2001).

1.2.1 Structure of Arrestins
Structurally, arrestins are commonly characterized as having an elongated shape
consisting of two domains (N-domain and C-domain) made up of β-sheets that are
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connected by a short hinge (Moore et al., 2007). Embedded between the two domains of
the molecule is a central polar core of buried salt bridges that functions to regulate
affinity of interaction with phosphorylated receptors. The proteins also contain an
extended C-terminal tail that that is connected to the body of the C-domain by a flexible
linker (Moore et al., 2007). It has been proposed that while GPCRs interact with arrestins
on their concave side, other arrestin interacting proteins bind on their convex side
(Gurevich & Gurevich, 2013). When a receptor binds it may cause a substantial
conformational rearrangement of arrestin involving movement of the two domains
relative to each other (Vishnivetskiy et al., 2002). This process may be dependent on the
length of the hinge connecting both domains since it has been shown that decreasing the
length of the hinge also reduces the amount of active receptor-bound arrestin
(Vishnivetskiy et al., 2002).

1.2.2 β-arrestin Interaction With GPCRs
Arrestins are multifunctional adaptor proteins that bind to GPCRs to exert a
regulatory role in which they can mediate different forms of ligand directed functional
signaling as well as internalization of the GPCR, a mechanism of GPCR desensitization
(Fig. 1.1). Upon agonist binding and activation, in addition to activation of multiple
signaling transduction pathways, agonist activation also promotes phosphorylation of the
receptor by G-protein coupled receptor kinases (GRKs) (Park et al., 2016). This promotes
the translocation and binding of β-arrestins, which serves to uncouple receptors from
heterotrimeric G-proteins and terminate signalling. β-arrestins can then function as
adaptors, linking the receptor to components of clathrin endocytic machinery such as
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Figure 1.1

Schematic illustration of β-Arrestin-dependent endocytosis and

signalling of GPCRs. Agonist activation promotes the GRK2-mediated phosphorylation
that promotes the translocation and binding of β-arrestins, which serves to uncouple
receptors from heterotrimeric G-proteins. β-Arrestins function as adaptor proteins that
interact with both clathrin and β2-adaptin promoting the clathrin coated vesicle-mediated
endocytosis of many GPCRs. β-Arrestin interactions with a variety of proteins allows for
the coupling of GPCRs to a variety of different signal transduction pathways whose
activation may be independent of heterotrimeric G-proteins. (Adapted from Magalhaes et
al., 2012)
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clathrin and adaptin, thereby promoting clathrin coated vesicle-mediated endocytosis of
the receptor (Ferguson 2001). The internalized receptor may then be targeted for
degradation to the lysosome or in some cases undergo receptor dephosphorylation and be
sent back to the cell surface for reactivation as a fully functional receptor (Ferguson
2001). Almost all cell membrane receptors, including GPCRs, exhibit these common
properties for internalization, from the plasma membrane to the cytoplasm, in response to
ligands.
Studies done over the past few years have demonstrated that β-arrestins not only
induce GPCR desensitization, but also can function as GPCR signal transducers. They
can form complexes by binding to several signaling proteins, including Src-family
tyrosine kinases and components of the ERK1/2 and JNK3 MAP cascades (Moore et al.,
2007). In addition to ERK activation, they have also been shown to be able to scaffold
numerous other proteins important for regulation of signalling including AKT, PI3
kinase, phosphodiesterases, transcription factors, and small GTPases (Magalhaes et al.,
2012). Evidence now suggests that GPCRs can selectively activate signalling pathways
that are predominantly β-arrestin mediated. This is partly dependent on the nature of the
ligand; interaction with the receptor determines the conformational state of the ligand and
preference for binding either heterotrimeric G-proteins or β-arrestins (Magalhaes et al.,
2012).

1.2.3 Vacuolar Protein Sorting-Associated Protein 26 (VPS26)
The retromer complex is a large multimeric complex that consists of the five
subunits SNX1, SNX2, Vps26, Vps29 and Vps35 (Shi et al., 2006). In humans, this
complex is thought to mediate retrograde transport of proteins from endosomes to the
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trans-Golgi network (TGN) as well as recycling of cargo proteins from the endosome to
the plasma membrane (Shi et al., 2006). The Vps26 subunit of this complex has two
isoforms within the mouse genome, Vps26A and Vps26B, that can both interact with
other retromer subunits (Gallon et al., 2014). Vps26 has previously been shown to be
required for embryonic development in mice (Lee et al., 1992). It has also been
demonstrated that Vps26 protein expression is decreased in patients with Alzheimer’s
disease (Small et al., 2005). Therefore it is an important protein in mammalian
physiology.
The structure of Vps26A has recently been solved using x-ray crystallography and
determined to be a structural relative of the arrestin family of proteins (Shi et al., 2006).
Though Vps26 shares little sequence homology with the arrestin family, it shows a high
degree of structural similarity and shares the same overall protein fold. Interestingly, an
unusual characteristic of the arrestin family is the polar core embedded between its two
domains (N-domain and C-domain) (Shi et al., 2006). This characteristic is also shared by
Vps26, which also contains a polar core, though there is little sequence homology
between the polar residues (Shi et al., 2006).

1.2.3 β-arrestin Gene Knockouts
Considering the number of distinct GPCRs expressed in the mammalian genome,
the fact that there are only two β-arrestin subtypes expressed ubiquitously is rather
remarkable and demonstrates their physiological importance (Gurevich & Gurevich,
2013). Therefore, it can be expected that the genetic deletion of arrestins give a distinct
phenotype. While β-arrestin1 knockout mice and β-arrestin 2 knockout mice exhibit
altered functional phenotypes, a β-arrestin1/2 double knockout has been shown to be
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embryonically lethal (Bohn et al., 1999; Conner et al., 1997; Pierce & Lefkowitz, 2001).
This is similarly seen in Drosophila, where a knockout of the β-arrestin analog Kurtz
results in a broad lethal phase during embryogenesis (Roman et al., 2000). Since the
double knockout of β-arrestin1/2 is embryonically lethal, and the individual knockouts of
either β-arrestin lack an extreme phenotype, it can be implied that there is a functional
redundancy between the two proteins. This is further supported by the similarity in tissue
expression of the two genes (Sterne-Marr et al., 1993), as well as by data suggesting that
both proteins bind a range of receptors with similar levels of affinity (Gurevich et al.,
1995).

1.3 PDZ Proteins
PDZ domains are highly abundant protein-protein interaction domains of
approximately 80-90 amino acids residues (Fan & Zhang, 2002). They were originally
discovered in, and thereby named after, the proteins postsynaptic density 95 (PSD-95),
disks-large-1 (DLG), and Zonula occludens 1 (ZO-1) (Kennedy, 1995). Approximately
400 PDZ domains have been recognized, in over 200 proteins, within the human genome
(Wang et al., 2010). A large majority of PDZ domain containing proteins serve primarily
scaffolding functions, although some also have catalytic functions. While some PDZ
proteins contain only PDZ domains, such as PDZ domain containing protein PDZK1
which contains 4 PDZ domains, other PDZ proteins contain additional functional
domains (Figure 1.2). These domains can include Src-homology 2 (SH2) domains,
phosphotyrosine binding (PTB) domains, calmodulin kinase-like (CaMK) and Ras
associated (RA) domains, among others (Dunn & Ferguson, 2015; Harris & Lim, 2001;
Magalhaes et al., 2012). The MAGUK proteins are a family of PDZ proteins that, in
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Figure 1.2

Molecular topology of PDZ domain-containing proteins. (Adapted

from Dunn & Ferguson, 2015)
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addition to one to three PDZ domains, are characterized as containing a Src- homology 3
(SH3) domain and a catalytically inactive guanylate kinase-like (GK) domain (Anderson,
1996; Dimitratos et al., 1999; Zheng et al., 2011).
Combining PDZ domains with other functional domains allows PDZ domain
containing proteins to mediate many cellular functions such as epithelial cell polarity
(Bilder et al., 2003), neuronal signal transduction (Kim & Sheng, 2004), protein
trafficking and recycling (Roche et al., 2001), cytoskeleton dynamics related cell growth
(Voltz et al., 2001), and hair cell stereociliar development (Reiners et al., 2006).

1.3.1 Structure of PDZ Domains
Since first solving the structure of PDZ3 in PSD95 (Doyle et al., 1996), the
structures of hundreds of PDZ domains have been crystalized. Most PDZ domains share
similar globular structures that are characterized as containing two α-helices and six βstrands. The β-sheets together form a partially open barrel that is covered by an α-helix
on each opening (Doyle et al., 1996; Fanning & Anderson, 1996; Lee & Zheng, 2010). In
most PDZ domains the N- and C- terminals lie in close proximity and opposite to the
hydrophobic ligand binding groove. This cup-like binding pocket contains the highly
conserved Gly-Leu-Gly-Phe (GLGF) motif (Harris & Lim, 2001). This motif is unique to
PDZ domains and is thought to facilitate hydrogen bond formation and binding of ligands
to the domain. This normally occurs through the amide side chains of the GLGF motif
and a carboxylate group on the ligand (Sheng & Sala, 2001). In some PDZ domains,
residues such as serine, threonine, or phenylalanine can replace the first glycine residue
of the GLGF motif (Sheng & Sala, 2001). Differences in the domains have also been seen
with the second and fourth hydrophobic amino acid residues in the motif, which can be
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valines or isoleucines. This variation within the GLGF motif contributes to specificity in
PDZ domain interactions (Garner et al., 2000; Harris & Lim, 2001; Sheng & Sala, 2001;
Subbaiah et al., 2011).

1.3.2 Characterization of PDZ-mediated Interactions
PDZ binding peptide screening studies have established that many PDZ domain
containing proteins have the ability to bind multiple targets with comparable affinities.
This ability is likewise seen with PDZ-binding motifs, which have been shown to be able
to interact with a wide variety of PDZ domain containing proteins (Songyang et al., 1997;
Zhang et al., 2006). The promiscuity of PDZ interactions is unexpected given the
importance of PDZ domain containing proteins in multiple diverse cellular processes and
within a variety of living organisms. However, this phenomenon may in part be defined
by limited and specific spatial distributions of certain PDZ motif- and domain- containing
proteins (Songyang et al., 1997; Zhang et al., 2006).
PDZ domains interact with specific sequences of three amino acids, called PDZbinding motifs, often found on carboxyl terminal targets (Kim & Sheng, 2004; Lee &
Zheng, 2010). PDZ domains have different affinities for PDZ-binding motifs and
therefore are traditionally classified into three classes: Class I PDZ domains
preferentially bind to the S/T-X-Φ motif, Class II domains selectively bind to the Φ-X-Φ
motif, while Class III domains prefer the Ψ-X-Φ motif (where Φ indicates any
hydrophobic amino acid, Ψ represents any acidic amino aid residue, and X stands for any
amino acid) (Doyle et al., 1996; Dunn & Ferguson, 2015; Songyang et al., 1997).
However, it is worth mentioning that there are still some PDZ domains that cannot be
categorized into any of these specific classes.
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Although the majority of PDZ domain containing proteins bind to a PDZ binding
motif found on the carboxyl terminal of protein targets, there is accumulating evidence
that suggests some PDZ domains may bind to internal PDZ binding motifs contained
within target proteins (Harris & Lim, 2001; Mu et al., 2014; Trejo, 2005). An example of
this type of interaction has been demonstrated previously to occur with both PDZ
proteins syntropin and PSD-95 to the internal β-hairpin finger structure found in neuronal
nitric oxide synthase (nNOS) (Christopherson et al., 1999). This β-hairpin binds PDZ
domains by replacing the conventional c-terminal carboxylate group with a sharp β-turn
(Christopherson et al., 1999). Another example of this is the interaction between PDZ
protein Par-6 and the internal binding motif found in Pals1 protein (Penkert et al., 2004).
In this complex, the Pals1 binding motif forms an extended conformation similar to the
one seen in the nNOS-PDZ domain interaction. The binding of Pals1 induces a
conformational change in the ligand binding groove of Par-6, which may occur due to
salt bridges formed between the two proteins (Penkert et al., 2004). Other examples of
internal PDZ binding motifs interactions described in the literature include: the
interaction between PDZ protein Dvl and internal motifs found in Frizzled and Idax, PDZ
binding of nNOS to Vac14, and the interaction of HtrA1/2/3 with internal sequences of
misfolded polypeptides (Lemaire & McPherson, 2006; London et al., 2004; Runyon et
al., 2007; Wong et al., 2003). It has yet be be determinded if proteins containing an
internal PDZ binding motif undergo a shift in conformation upon binding to a PDZ
domain (Lee & Zheng, 2010).
Though most PDZ proteins studied thus far have been monomers, it has been
established that certain PDZ domains dimerize into either homodimers or heterodimers,
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often without disruption of peptide binding (Hillier et al., 1999; Lau & Hall, 2001; Xu et
al., 1998). It is thought that as many as 30% of PDZ domains dimerize with low
micromolar affinities that appear to be more specific than PDZ-ligand binding, therefore
influencing the specific make up of protein complexes (Chang et al., 2011). Studies have
shown that these interactions can occur through multiple mechanisms. For example, the
PDZ domain of shank1 and GRIP1 PDZ6 form back-to-back homodimers through
interactions between their conserved β2-β3 loops and N-terminal β1-strands, while
concurrently leaving their peptide binding sites open for interaction (Im, Lee, et al., 2003;
Im, Park, et al., 2003). A novel form of dimerization occurs with the second PDZ domain
of ZO-1 that forms homodimers through symmetrical swapping of β-strands in the
domains. The ZO-1 homodimer arranges such that the peptide binding site still remains
accessible, for both domains, on either side of the dimer (Chen et al., 2008; Fanning et
al., 2007). Although there are exceptions, it seems PDZ domain dimers often leave the
peptide binding site available, thus encouraging binding partners while also forming
another means of regulation for these interactions.
PDZ domains are largely characterized as protein-protein interaction modules,
however it has been shown that some PDZ domains can also bind to lipids such as
phosphoinositides (PIPs) (Zimmermann et al., 2002). As one of the phospholipid
components of mammalian cell membranes, phosphatidylinositol can serve either as a
precursor for second messengers or as a signaling molecule on the membrane that
regulates the localization of protein complexes (Di Paolo & De Camilli, 2006). PIPs can
control a broad range of cellular processes, such as the activity of ion channels and
transporters, membrane and actin dynamics, cell growth and differentiation, and vesicular
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trafficking (Balla et al., 2009). Therefore, interactions between PDZ proteins and PIPs
may provide an essential method of regulation for PDZ complexes, further illustrated by
recent estimates that as much as 40% of all PDZ domains interact with phospholipids
(Chen et al., 2012; Gallardo et al., 2010). These associations have been shown to occur
through multiple mechanisms such as electrostatic interactions, membrane penetration,
and specific PIP binding with basic clusters found in the PDZ domains (Gallardo et al.,
2010). However, there is still no consensus on where the PIP binding site lies in PDZ
domains. While some studies suggest a synergistic interaction, others suggest competitive
binding between PIPs and the peptide ligand (Ivarsson et al., 2011; Wu et al., 2007;
Zimmermann et al., 2002). Further studies are required to fully understand the interplay
between lipid-PDZ domain interactions, along with the consequential physiological
implications.

1.3.3 Regulation of PDZ Proteins
PDZ interactions are regulated in several ways, as can be expected from their
critical functions in assembling protein complexes. One form of regulation includes
phosphorylation of serine, threonine, or tyrosine resides within the PDZ binding motif
(H.-J. Lee & Zheng, 2010). Phosphorylation of the PDZ binding motif, in some cases,
can disrupt and reduce PDZ domain binding. This is seen in the interaction between the
Kir2.3 channel and the PDZ domains of PSD-95 (Cohen et al., 1996). However, in other
cases, phosphorylation has also been shown to increase affinity for PDZ domain binding,
such as in the binding of PDZ proteins PDZK1, IKEPP or EBP50 to the C-terminal of
MRP2 (Hegedüs et al., 2003). Thus, phosphorylation of PDZ binding motifs may serve as
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a functional switch, allowing for different conformations that each optimally bind to a
different PDZ domain (Ivarsson, 2012).
Another method of regulation includes allosteric regulation, which can modulate
the binding preference of PDZ domains (H.-J. Lee & Zheng, 2010). For example, binding
of the small GTPase Cdc42 to a CRIB domain adjacent to the PDZ domain of Par6 can
change the dynamics of the protein, from a fluid low-affinity state to a rigid high-affinity
state with an increased affinity for its carboxy-terminal ligand (Peterson et al., 2004).
Some PDZ domains can even self regulate through the process of autoinhibition. Many
PDZ domains containing proteins also contain a PDZ binding motif at their distal Cterminal tail, which can fold back to bind with the PDZ domain, and thus prevent binding
of other ligands (Ye & Zhang, 2013). This mechanism has been seen in PDZ proteins
such as X11α, tamalin and NHERF1 (H.-J. Lee & Zheng, 2010; Ye & Zhang, 2013).
Finally, it has been shown that PDZ interactions can also be regulated by environmental
changes in pH or ionic strength (Harris et al., 2003; Chi et al., 2006).

1.3.4 Regulation of GPCRS by PDZ Proteins
Numerous GPCRs contain a PDZ binding motif on their C-terminal tail and thus
can interact with PDZ proteins to form multiprotein complexes. Since PDZ domain
containing proteins are one of the most abundant types of GPCR-interacting proteins, it
comes as no surprise that they have been shown to be important regulators of various
properties including receptor trafficking, signalling, and cellular distribution (Table 1.1)
(Dunn & Ferguson, 2015; Magalhaes et al., 2012). GPCRs can bind multiple PDZ
proteins and vice versa with different regulatory mechanisms, in fact studies show PDZ
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PDZ Protein

Trafficking Function

GPCR

PSD-95

↓ Endocytosis
↑ Recycling
↑ Membrane localization
↑ Endocytosis

β1AR, 5-HT2AR
D1 R
GPR30
5-HT2CR, D1R

SAP97

↓ Endocytosis
↑ Recycling

CRFR1, 5-HT2AR
β1AR

SAP102

↓ Mobility

A2A receptor

MAGI-2

↓ Endocytosis
↑ Endocytosis
↑ Membrane localization

VPAC1
β1AR
mGluR1a

NHERF1

↓ Endocytosis
↑ Recycling
↑ Membrane localization
↑ Endocytosis

β2AR, TPβ
β2AR, human κopioid receptor
SSTR5, PTH1R
CCR5, platelet-activating factor
receptor, P2Y12R

PDZK1

↓ Endocytosis
↑ Membrane localization

5-HT2AR
hIPR

PDZK2

↑ Membrane localization

hIPR

Spinophilin

↓ Endocytosis
↑ Endocytosis

α2AR
μOR

MUPP1

↑ Membrane localization
5-HT2AR
↑ Tight junction localization SSTR3

SNX27

↑ Recycling

β2AR, β1AR, SSTR5

CAL

↓ Membrane localization
↓ Recycling
↑ Golgi localization

β1AR, SSTR5
β1AR
SSTR5

Table 1.1

Effect of PDZ proteins on GPCR trafficking. (Modified from Dunn &

Ferguson, 2015)
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proteins can have distinct functions dependent on the specific GPCR-PDZ interaction in
question (Dunn & Ferguson, 2015). For example, it has been documented that GPCR β1adrenergic receptor (β1AR) can be regulated by various PDZ proteins in various different
manners. While PDZ domain containing protein PSD-95 has been shown to promote
membrane localization of the β1AR through inhibition of receptor internalization, PDZ
protein SAP97 seems to do so by promoting receptor recycling to the membrane (Hu et
al., 2000; Gardner et al., 2007). However, PDZ proteins MAGI-2 and Cal have both been
shown to decrease cell surface expression of the β1AR, though through different
mechanisms. While MAGI-2 promotes receptor internalization into endocytic vesicles,
Cal retains the receptor within the Golgi apparatus (Xu et al., 2001; He et al., 2004).
Thus, PDZ proteins are important regulators of GPCR function and a greater
understanding of these interactions will not only further our understanding of GPCR
function, but also potentially aid in the development of new pharmaceuticals.

1.4 Corticotropin-releasing factor receptors (CRFRs)
The corticotropin releasing factor receptors, CRFR1 and CRFR2, are class B
GPCRs that share 70% amino acid sequence homology (Bale et al., 2002; Grigoriadis et
al., 1996). However these receptors display differences in expression profiles, while
CRFR1 is mainly expressed in the brain within regions such as the cerebral cortex,
cerebellum, medial septum, and anterior pituitary, CRFR2 is mainly expressed in
peripheral regions such as the heart and skeletal muscle (Bale et al., 2002). Thus, CRFR1
seems to be predominantly involved in regulating the physiological functions of the
central nervous system.
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Upon CRF activation, both receptors primarily signal through coupling via Gαs,
which activates adenylyl cyclase, leading to increases in cAMP, and downstream
activation of protein kinase A (PKA). The activation of PKA can lead to the activation of
a diverse range of signalling molecules such as: guanylyl cyclase, transcription factor
NF-kB, glycogen synthase kinase-3 and the Wnt/β-catenin pathway (Aggelidou et al.,
2002; Khattak et al., 2010; Zhao & Karalis, 2002). Importantly, CRFR1 has also been
shown to activate the MAPK/ERK signalling pathway (Grammatopoulos, 2012).
It has been shown CRFR1 internalization is initiated by binding of β-arrestin to
GRK-phosphorylated receptors, which also acts to attenuate signalling of the receptor
(Holmes et al., 2006). Upon internalization, the CRFR1-β-arrestin complex has been
shown to act differently in various experimental settings. While some studies show that
the two proteins form a stable complex which internalizes as one unit into endocytic
vesicle, others show that β-arrestin dissociates and remains at plasma membrane, where it
can then act as a scaffolding protein to facilitate signalling pathways such as the MAPK
cascade (Holmes et al., 2006; Markovic et al., 2006; Perry et al., 2005; Punn et al., 2006;
Rasmussen et al., 2004) Some studies have also suggested that internalization of CRFR1
can be independent of β-arrestin recruitment (Rasmussen et al., 2004). This indicates that
the mechanisms of CRFR1 internalization are diverse; furthermore this versatility
indicates that internalization of the receptor is not solely dependent on receptor activation
and signalling. Upon internalization, CRFR1 initially colocalizes with GTPase Rab5 in
early endosomes, and then transitions to Rab4 positive endosomes to allow the recycling
of the receptor (Holmes et al., 2006).
CRFR1 has been shown to have a ten-fold higher affinity for CRF than CRFR2
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(Dautzenberg & Hauger, 2002). CRF is a neuropeptide, commonly released as a response
to stressors, which initiates the hypothalamic-pituitary-adrenal (HPA) axis (Bale & Vale,
2004). Any actual or perceived stressor causes the release of CRF from neurons, within
the paraventricular nucleus in the hypothalamus, into the hypophyseal portal vein system
towards the anterior pituitary. Here CRF acts on CRFRs to activate release of
adrenocortictoropic hormone (ACTH) secretion into systemic circulation, which
subsequently causes the adrenal cortex to synthesize and release glucocorticoids such as
cortisol into the bloodstream (Bale & Vale, 2004). Following exposure to stress, cortisol
acts to regulate glucose levels, ion transport, and the immune response (Tsigos &
Chrousos, 2002). CRF is therefore important for coping with stressors and restoring
homeostasis in the body. However, elevation in levels of CRF and chronic exposure to
cortisol has been shown to correlate with anxiety disorders and depression, supported by
evidence of increased levels of CRF within extra-hypothalamic brain regions in the postmortem brains of depressed suicide victims (Arborelius et al., 1999; Austin et al., 2003;
Gold et al., 1996; Holsboer, 1999). Thus, targeting the CRF system seems may be
important for the treatment of mood disorders.
Perhaps, one of the most promising pharmacological targets for treatment of
mood disorders includes the CRFR1. Antagonists for this receptor have been shown to
have anxiolytic effects by decreasing the HPA response (Dautzenberg & Hauger, 2002;
Mansbach et al., 1997). Furthermore, knockout studies done in mice show that deletion of
the CRF receptors causes distinct phenotypes (Bale & Vale, 2004; Janssen & Kozicz,
2013). Mice deficient in CRFR1 display decreased levels of anxiety-like behavior and
have an impaired stress response. Conversely, mice lacking the CRFR2 seemed to display
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increased anxiety-like behavior and were hypersensitive to stress (Bale & Vale, 2004;
Janssen & Kozicz, 2013).
The 5-HT2AR is another GPCR that has been implicated in regulation of mood
disorders and mental illness, particularly depression (Catapano & Manji, 2007).
Interestingly, it has previously been shown that the stimulation of CRFR1 with CRF
results in enhanced signalling of the 5-HT2AR, in both cell cultures and mouse prefrontal
cortical neurons (Magalhaes et al., 2010). Specifically, infusion of both CRF and DOI, a
5-HT2AR agonist, in mice led to a significant increase in anxiety-related behavior that
was not seen with DOI alone (Magalhaes et al., 2010). This sensitization of 5-HT2AR
signalling seems to be dependent on CRFR1 receptor endocytosis into endosomes, which
allows for recruitment of an intracellular pool of 5-HT2AR and thereafter rapid recycling
to the membrane. Blocking these processes seems to eliminate receptor crosstalk
(Magalhaes et al., 2010). Thus, this is a biochemical mechanism that relates CRF
mediated stress with enhanced anxiety behaviours mediated through the 5-HT2AR
(Magalhaes et al., 2010).
While CRFR2 does not contain a PDZ binding motif, CRFR1 and 5-HT2AR both
contain PDZ binding motifs on their distal C-terminal tails (Romero et al., 2011).
Crosstalk between the two receptors, which allows for CRFR1-mediated sensitization of
5-HT2R IP3 signalling, seems to be mediated through PDZ protein interactions
(Magalhaes et al., 2010). When the PDZ binding motif on either receptor is deleted, it
attenuates the CRFR1-dependent increases of 5-HT2AR at the cell surface as well
sensitization of 5-HT2R signalling (Magalhaes et al., 2010). However, the identity of the
PDZ protein mediating this crosstalk still remains unknown. Nonetheless, this
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phenomenon seems to form a link between CRF-mediated stress responses to 5-HT2Rmediated anxiety and depression (Magalhaes et al., 2010; Magalhaes et al., 2012).
This is supported by findings that suicide victims with depression also seemed to
possess enhanced levels of CRF in serotonergic neurons within the raphe nuclei (Austin
et al., 2003). This is of importance since it has also been found that CRF can activate
serotonergic neurons in the raphe nuclei that contain efferents to the medial prefrontal
cortex, to ultimately initiate anxiety-like behaviour (Meloni et al., 2008). Therefore,
CRFR1 activation sensitizes 5-HT2R-mediated anxiety behaviours in response to stress,
and PDZ proteins may be important regulators of this process (Magalhaes et al., 2010).
Taken together, PDZ protein regulation of CRFR1 may prove to play an integral role in
initiation of mental illness, and therefore may foreseeably be a promising
pharmacological target when treating psychiatric disease.

1.5 Regulation of CRFR1 and 5-HT2R by PDZ proteins
It has thus far been determined that PDZ proteins are important regulators of
GPCR signaling and trafficking properties. However, while the evidence for this is
increasing, still very little is known about the mechanism behind this mode of regulation.
Interestingly, it has previously been shown that PDZ protein PSD95 regulates trafficking
properties of the GPCR CRFR1 (Dunn et al., 2016). While overexpression of GFP-PSD95 in HEK293 cells reduces CRF-stimulated CRFR1 internalization, shRNA knockdown
of endogenous PSD-95 expression increases CRFR1 endocytosis (Dunn et al., 2016).
Deletion of the PDZ binding motif in CRFR1 (consisting of the three amino acids TAV),
such that the receptor can no longer bind PDZ domain containing proteins, causes an
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increase in CRFR1 internalization and prevents PSD-95-dependent regulation of HACRFR1 internalization (Dunn et al., 2016).
In the same study it was also shown that PSD95 antagonizes β-arrestin2
recruitment to CRF-agonist stimulated CRFR1 (Dunn et al., 2016). It was shown, through
use of BRET, that overexpressing PSD95 decreases CRF-stimulated Barr2 recruitment to
CRFR1 and reduces the maximal response for CRF-stimulated β-arrestin translocation.
Conversely, shRNA knockdown of PSD95 was shown to increase β-arrestin2 recruitment
to CRFR1 and enhance the maximal response of β-arrestin translocation (Dunn et al.,
2016). Thus, it appears that PSD-95 antagonizes CRFR1 internalization by preventing βarrestin interactions required for the endocytosis of the receptor, thereby providing a
potential mechanism for PDZ protein regulation of GPCR trafficking (Dunn et al., 2016).
This form of PDZ protein regulation of GPCRs is also seen in a study done by
Schmid and Bohn (2010), this time with the 5-HT2AR. In this study, 5-HT2AR was
immunoprecipitated from the frontal cortex of both WT and βarr2-KO mice following 5HTP agonist treatment. In WT mice, PSD-95 was displaced from the 5-HT2AR in
response to agonist treatment and 5-HT2AR increased associations with βarrestin2
(Schmid & Bohn, 2010). However, for the Barr2 KO mice, in the absence of βarrestin2,
PSD-95 was not displaced from the 5-HT2AR in response to agonist (Schmid & Bohn,
2010). This suggests that the interplay between βarrestin2 and PDZ protein PSD-95 may
determine whether the receptor is internalized or remains on the cell surface through
regulation of β-arrestin recruitment (Schmid & Bohn, 2010). Additionally, perhaps this
does not only apply to GPCRs CRFR1 and 5-HT2AR, but is a general mechanism of
regulation by PDZ proteins for GPCR trafficking and signalling.

21

1.6 Hypothesis and Objectives
This thesis will explore the hypothesis that PDZ domain-containing proteins
interact with β-arrestin-2 to modulate arrestin recruitment and receptor trafficking. To
test this hypothesis, our objectives were:

1. Determine if PDZ proteins are capable of interacting with β-arrestin2.
2. Determine the mechanism of interaction between PDZ proteins and βarrestin2. What amino acid residues or protein interaction domains are
involved for both proteins?
3. Determine whether this interaction is important for regulation of β-arrestin2
recruitment to GPCRs and trafficking of GPCRs.
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Chapter 2: Materials and Methods
2.1 Materials
ECL Western blotting detection reagents were purchased from Biorad (Mississauga, ON,
Canada). Rabbit anti-GFP antibody was obtained from Invitrogen/Life Technologies
(Burlington, ON, Canada). Anti-Flag M2 Affinity Gel, rabbit anti-Flag antibody, and all
other biochemical reagents were purchased from Sigma-Aldrich (Oakville, ON, Canada).

2.2 Plasmids
HA-tagged CRFR1 was described previously (Holmes et al., 2006). GFP-PSD-95 was
provided by Dr. Gregory Dekaban (Robarts Research Institute). His-MAGI-1 was
provided by Dr. Randy Hall (Emory University, School of Medicine). YFP-PDZK1 was
described previously (Walther et al., 2015). All FLAG and YFP tagged β-arrestin2
mutants were generated using site-directed mutagenesis with the Q5 site-directed
mutagenesis kit (New England Biolabs). Primers used are outlined in Table 2.1.

2.3 Cell Culture and Transfection
Human embryonic kidney (HEK293) cells were maintained in Eagle’s minimal essential
medium supplemented with 10% fetal bovine serum. Cells were seeded on 10-cm dishes
at 70–80% density 24 h prior to transfection. Transfections were performed using a
modified calcium phosphate method. Empty pcDNA3.1 vector was used to equalize the
total amounts of plasmid cDNA used to transfect cells. 18 h post-transfection, cells were
washed with phosphate-buffered saline (PBS). All experiments were conducted 48 h after
the initial transfection.
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Isoform Forward Primer (5’à3’)

Reverse Primer (5’à3’)

K34Q

TCACTTGGACcaaGTGGATCCTG

TCCACAAAGTCACGCTTG

K34A

TCACTTGGACgcaGTGGATCCTG

TCCACAAAGTCACGCTTG

V54D

GGACCGGAAAgacTTTGTGACCCTC

TTCAAGTAGTCAGGATCC

R170E

GCTTATCATCgaaAAGGTACAGTTTGC

CGCACGGAGTTCCTTTTG

Q173L

CAGAAAGGTActgTTTGCTCCTG

ATGATAAGCCGCACGGAG

Q173A

CAGAAAGGTAgcgTTTGCTCCTGAGACAC ATGATAAGCCGCACGGAG

F174L

AAAGGTACAGttgGCTCCTGAGAC

CTGATGATAAGCCGCACG

F174A

AAAGGTACAGgctGCTCCTGAGAC

CTGATGATAAGCCGCACG

A175F

GGTACAGTTTtttCCTGAGACACC

TTTCTGATGATAAGCCGC

A175G

GGTACAGTTTggtCCTGAGACAC

TTTCTGATGATAAGCCGCAC

A175L

GGTACAGTTTcttCCTGAGACACC

TTTCTGATGATAAGCCGC

Table 2.1.

Primers used for site directed mutagenesis of β-arrestin2.
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2.4 Co-immunoprecipitation
Transfected HEK 293 cells were seeded on 10 cm dishes the day before the experiment.
Cells were lysed in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Triton X100) containing protease inhibitors (1 mM AEBSF, 10 mg/ml leupeptin, and 5 mg/ml
aprotinin) for 20 min on a rocking platform at 4ºC. Samples were collected into 1.5 mL
Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4 ºC to pellet insoluble
material. A Bronsted-Lowry protein assay was performed and 400 μg of protein was
incubated for 2-4 h at 4ºC with anti-FLAG beads. After incubation, beads were washed 3
times with cold lysis buffer and eluted with 100 μl of SDS loading buffer containing βmercaptoethanol before being stored overnight at -20 °C. Samples were separated by
SDS-PAGE, transferred to a nitrocellulose membrane, and immunoblotted to identify coimmunoprecipitated GFP or YFP tagged PDZ proteins (rabbit anti-GFP, 1:1000). An
additional Western blot was performed to examine FLAG-βarrestin2 (rabbit anti-FLAG,
1:1000) protein expression.

2.5 Western Blot Analysis
Eluted proteins were applied to 10% SDS-polyacrylamide gel electrophoresis (30%
acrylamide mix, 1.5 M tris-HCl, 20% SDS, 10% ammonium persulfate and TEMED).
Separated proteins were then transferred to nitrocellulose membranes that were blocked
with 10% powdered milk in TBS for 1h. Membranes were then blotted overnight by
incubation with the appropriate antibody at 4°C. Membranes were then washed at least
three times with 1X TBS containing 0.05% Tween 20, and further incubated with a
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horseradish peroxidase- conjugated secondary antibody (1:10,000) for 1h. Membranes
were finally washed again with 1X TBS containing 0.05% Tween 20 three times before
being incubated with enhanced chemiluminescence Western blotting detection reagents
and visualized using a Chemidoc Imaging System.

2.6 Bioluminescent Resonance Energy Transfer
HEK 293 cells were co-transfected with the indicated cDNA using Lipofictamine 2000
into 96 well plates. β-arrestin was tagged with Renilla luciferase (Rluc) and used as the
energy donor while CRFR1 was tagged with YFP and used as the energy acceptor. The
reaction was then started, 48h after transfection, by the addition of Coelenterazine to each
well at a final concentration of 5 μM. Cells were also treated with 500 nM CRF and the
BRET ratio was determined over time. Furthermore, multiple concentrations of CRF
were employed to create a dose–response curve of β-arrestin2 recruitment following 20
min stimulation. Signals were collected on a Synergy Neo2 plate reader (Thermo Fisher)
using 460/40-nm (luciferase) and 540/25-nm (YFP) band pass filters. The BRET ratio
was determined by calculating the ratio of light that passed by the 540/25 filter to that
passed by the 460/40 filter.

2.7 Protein Alignments and Figures
Structural and sequential alignments of proteins were determined using the web program,
protein BLAST with the Molecular Modeling Database (MMDB)
(http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.shtml). Cn3D 4.3
(http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3dmac.shtml) was used to display the
structures. All structural figures were generated using PyMOL (www.pymol.org).
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2.8 Statistical Analysis
Densitometric data were normalized first for protein expression and the maximum value
was set to 100, with all other values displayed as percentage thereof. All measurements
are represented as mean ± SEM. Comparisons were performed using either a two-tailed
student’s t test or a one-way analysis of variance test (ANOVA) that was followed by a
post-hoc Dunnett’s multiple comparisons test to determine significance. * indicates a P
values less than 0.05 and is considered to be significant.
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Chapter 3: Results
3.1 PDZ proteins interact with β-arrestin2
Many PDZ proteins have been documented to regulate GPCR trafficking
properties (Dunn & Ferguson, 2015). It has also previously been shown that
internalization of many receptors is β-arrestin dependent, including CRFR1 (Holmes et
al., 2006; Moore et al., 2007). The PDZ protein PSD-95 has been shown to regulate βarrestin2 recruitment and thereby receptor trafficking properties for GPCRs CRFR1 and
5-HT2AR (Dunn & Ferguson, 2015; Dunn et al., 2016; Schmid & Bohn, 2010). CRFR1
endocytosis has also previously shown to be antagonized, in PDZ-motif dependent
manner, by PDZ proteins SAP97 and CAL (Dunn et al., 2013; Hammad et al., 2015).
Meanwhile, 5-HT2AR endocytosis has previously been shown to be supressed by PDZ
proteins PSD95, SAP97 and PDZK1 (Dunn et al., 2014; Walther et al., 2015; Xia et al.,
2003). Therefore, to further understand PDZ protein regulation of GPCRs, and whether
this is mediated by interactions with β-arrestin2, we sought to further characterize the
interaction between the two protein families. To do this, we performed a series of coimmunoprecipitation experiments in HEK293 cells. In these studies, we looked at the
interaction between β-arrestin2 and various PDZ proteins that each contained a different
assortment of protein interaction domains.
First, we assessed whether GFP-PSD95 could by co-immunoprecipitated with βarrestin2 in HEK 293 cells that were co-transfected with FLAG-β-arrestin2 (Fig. 3.1).
PSD-95 contains several protein interaction domains including three PDZ domains, an
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Figure 3.1:

GFP-PSD95 co-immunoprecipitates with FLAG-β-arrestin2 in

HEK293 cells. Representative immunoblot of FLAG-β-arrestin2 co-immunoprecipitated
(IP) with GFP-PSD95 but not peGFP or GFP-Rab8. Transient transfections were
performed in HEK 293 cells as labeled. Samples were run using SDS-PAGE and
immunoblotted (IB) with rabbit anti-GFP and rabbit anti-FLAG. Data are representative
of three independent experiments.
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SH3 domain, and a GK domain. We found that GFP-PSD95 interacted with FLAG-βarrestin2 and therefore concluded one of the domains within PSD95 mediated the
interaction. As a negative control, we assessed whether FLAG-β-arrestin2 could interact
with peGFP or GFP-Rab8 and found it did not interact with either.
We next assessed whether YFP-MAGI1 could by co-immunoprecipitated with βarrestin2 in HEK 293 cells that were co-transfected with FLAG-β-arrestin2 (Fig. 3.2).
MAGI1 also contains several protein interaction domains including six PDZ domains, a
GK domain, and two WW domains. While MAGI1 contains PDZ domains and a GK
domain similar to PSD-95, it does not contain an SH3 domain. We found that YFPMAGI1 also interacted with FLAG-β-arrestin2 and therefore concluded that PDZ protein
interaction with β-arrestin2 must not be mediated through the SH3 domain. FLAG-βarrestin2 did not interact with negative controls peGFP or GFP-Rab8.
Finally, we assessed whether YFP-PDZK1 could by co-immunoprecipitated with
β-arrestin2 in HEK 293 cells that were co-transfected with FLAG-β-arrestin2 (Fig. 3.3).
The only protein interaction domains in PDZK1 are PDZ domains, to be exact four of
them. We found that YFP-PDZK1 also interacted with FLAG-β-arrestin2. Since PDZK1
only contains PDZ domains, this suggests that that the interaction between PDZ proteins
and β-arrestin2 is mediated through the PDZ domain. FLAG-β-arrestin2 did not interact
with negative controls peGFP or GFP-Rab8.
To further determine and characterize the interaction between β-arrestin2 and
PDZ proteins, which seemed to be mediated through the PDZ domain, we assessed
whether FLAG-β-arrestin2 could co-immunoprecipitated with any of the four isolated
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Figure 3.2.

YFP-MAGI1 co-immunoprecipitates with FLAG-β-arrestin2 in

HEK293 cells. Representative immunoblot of FLAG-β-arrestin2 co-immunoprecipitated
(IP) with YFP-MAGI1 but not peGFP or GFP-Rab8. Transient transfections were
performed in HEK 293 cells as labeled. Samples were run using SDS-PAGE and
immunoblotted (IB) with rabbit anti-GFP and rabbit anti-FLAG. Data are representative
of three independent experiments.
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Figure 3.3.

YFP-PDZK1 co-immunoprecipitates with FLAG-β-arrestin2 in

HEK293 cells. Representative immunoblot of FLAG-β-arrestin2 co-immunoprecipitated
(IP) with YFP-PDZK1 but not peGFP or GFP-Rab8. Transient transfections were
performed in HEK 293 cells as labeled. Samples were run using SDS-PAGE and
immunoblotted (IB) with rabbit anti-GFP and rabbit anti-FLAG. Data are representative
of three independent experiments.
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B

Figure 3.4.

The first PDZ domain of YFP-PDZK1 co-immunoprecipitates with

FLAG-β-arrestin2 in HEK293 cells. (A) Representative immunoblot of FLAG-βarrestin2 co-immunoprecipitated (IP) with YFP-PDZK1 and YFP-PDZ1 but not YFPPDZ2, YFP-PDZ3 or YFP-PDZ4. Transient transfections were performed in HEK 293
cells as labeled. Samples were run using SDS-PAGE and immunoblotted (IB) with rabbit
anti-GFP and rabbit anti-FLAG. (B) Immunoblots were analyzed by densitometry. Coimmunopreciptated PDZ domains were compared to full length PDZK1. Statistical
significance is assessed by one-way ANOVA followed by Dunnett’s multiple
comparisons post hoc test (*p < 0.05). Data are averaged means ± S.E.M. of three
independent experiments.
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YFP-tagged PDZ domains within PDZK1 (Fig. 3.4). This would not only further confirm
that this interaction occurs through the PDZ domain, but also determine the specificity of
the interaction and if it occurs through multiple domains. We found that FLAG-βarrestin2 interacted with only the first PDZ domain of PDZK1, indicating that this
domain may be important in mediating the interaction between β-arrestin2 and PDZK1.
Therefore, we have shown that multiple PDZ proteins are capable of interacting with βarrestin-2, and that PDZ proteins may mediate this interaction via the PDZ domain.

3.2 Characterization of residues within β-arrestin2 important for
PDZ-arrestin interactions
After previously looking at PDZ proteins, we next tried to determine what regions
or amino acids of β-arrestin-2 mediate arrestin-PDZ interactions. It has previously been
described that while there is little sequence similarity between Vps26 and arrestin family
members, the two protein families are structurally homologous (Shi et al., 2006). To
further explore the extent of similarity between Vps26A and arrestin family members, we
performed sequential and structural alignments summarized in Table 3.1. Structural
similarity was defined by average root mean square deviation (RMSD) in Angstroms (Å),
while sequence similarity was defined by % of similar amino acid residue identity.
Alignment of the amino acid sequence of mouse Vps26A showed low sequence
homology with bovine β-arrestin-2, β-arrestin-1, and S-arrestin as well as with cone
arrestin from ambystoma tigrinum. However, all arrestin family members showed a high
degree of structural similarity to mouse Vps26A, indicated by a low RMSD. The highest
degree of structural similarity seemed to be between Vps26A and β-arrestin-2, with a
RMSD of 1.94 Å (Table 3.1).
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Arrestin Proteins aligned with

PDB ID

RMSD

VPS26A (PDB: 4P2A)

Sequence
Homology

β-arrestin-2 (arrestin-3)

3P2D

1.94 Å

11%

Cone arrestin (arrestin-4)

1SUJ

2.16 Å

10%

S-arrestin (arrestin-1)

3UGX

2.27 Å

9%

β-arrestin-1 (arrestin-2)

1G4R

2.31 Å

11%

Table 3.1.

Structural and sequential alignment of mouse Vps26A protein with

arrestin family members.
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PDZ protein sorting nexin 27 (SNX27) was previously been shown to mediate
sorting of transmembrane cargo from endosomes to the plasma membrane (Lauffer et al.,
2010). The crystal structure of this protein determined that the PDZ domain of SNX27
bound the retromer subunit Vps26A (Gallon et al., 2014). Since Vps26A bound to the
PDZ domain of SNX27, and β-arrestin2 had close structural to Vps26A, it could be
extrapolated that perhaps β-arrestin2 also interacted with the PDZ domain of SNX27, as
well as other PDZ proteins. To explore this further, we did a structural alignment between
Vps26A and β-arrestin2, the most structurally similar arrestin to Vps26A. Shown in
Figure 3.5 are the crystal structures of mouse Vps26A bound to the PDZ domain of rat
SNX27 (PDB: 4P2A) and docked with the crystal structure bovine β-arrestin2 (PDB:
3P2D). Summarized in Table 3.2 are important residues within mouse VPS26A thought
to be important for interaction with rat SNX27 (Gallon et al., 2014). Also summarized are
the structurally analagous amino acids within bovine β-arrestin2, determined from the
structural alignment. These residues as observed in Figure 3.6 A-C, are highlighted in
yellow within the crystal structures of the two proteins.
To determine which β-arrestin-2 residues were important for interaction with PDZ
proteins, we created β-arrestin-2 substitution mutants of the residues determined to be
structurally analogous to Vps26A residues important for interaction with SNX27 (Table
3.2). To assess how these mutations affected β-arrestin2 interactions with PDZ proteins,
we performed co-immunoprecipitation experiment with the β-arrestin2 mutants and PDZ
protein PSD95 (Fig. 3.7). Along with β-arrestin2 substitution mutants K34Q, Q173L,
F174L, and A175F presumed to mediate PDZ domain interactions, we also tested
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Figure 3.5.

Structural similarities between mouse Vps26 and bovine β-arrestin2.

Vps26A is shown in a ribbon model in blue, β-arrestin-2 is shown in a ribbon model in
magenta, and the PDZ domain of SNX27 is shown in a ribbon model in green. Mouse
Vps26A bound to the PDZ domain of rat SNX27 was structurally aligned with bovine βarrestin-2. All structural figures with generated with Pymol (www.pymol.org).
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Amino acid residues in mouse

Structurally analogous amino

Vps26A important for

acid residues within bovine

interaction with rat SNX27

β-arrestin2

44 D

34 K

153 Q

173 Q

154 L

174 F

155 A

175 A

Table 3.2.

Summary of important residues within mouse Vps26A important for

interaction with rat SNX27 and the structurally analogous amino acids within
bovine β-arrestin2.
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The image part with relationship ID rId22 was not found in the file.
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C

Figure 3.6.

Crystal structure of amino acid residues within mouse VPS26A

important for interaction with rat SNX27 and the structurally analogous residues
within bovine β-arrestin2. Vps26A is shown in a ribbon model in blue, β-arrestin-2 is
shown in a ribbon model in magenta, and the PDZ domain of SNX27 is shown in a
ribbon model in green. (A) Crystal structure of mouse Vps26A bound to the PDZ domain
of rat SNX27. Highlighted in yellow are the residues within Vps26A thought to be
important to mediate this interaction (outlined in Table 2). (B) The crystal structure of
mouse Vps26A bound to the PDZ domain of rat SNX27 is structually aligned with
bovine β-arrestin-2. Highlighted in yellow are the residues within Vps26A thought to be
important to mediate the interaction with SNX27 as well as structually analogous
residues within β-arrestin-2 (outlined in Table 2). (C) A close up image of the residues
highlighted in yellow for both Vps26 and β-arrestin2.
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Figure 3.7.

C

The image part with relationship ID rId22 was not found in the file.

FLAG-β-arrestin2 mutants V54D and R170E increase co-

immunoprecipitation of GFP-PSD95. (A) Representative immunoblot of GFP-PSD95
co-immunoprecipitated (IP) with FLAG-β-arrestin2 and mutants forms of FLAG-βarrestin2 with substitutions K34Q, V54D, R170E, Q173L, F174L, and A175F. Transient
transfections were performed in HEK 293 cells as labeled. Samples were run using SDSPAGE and immunoblotted (IB) with rabbit anti-GFP and rabbit anti-FLAG. (B and C)
Immunoblots were analyzed by densitometry to quantify amount of PSD-95 coimmunoprecipitated to β-arrestin2 mutants compared to wild type (WT) β-arrestin2. Data
represents the mean ± SD of four independent experiments. *, p < 0.05.

40

β-arrestin2 mutants previously documented in literature for a point of reference. This
includes β-arrestin2 V54D, a dominant negative form of β-arrestin2 (Ferguson et al.,
1996), and β-arrestin2 R170E which is a constitutively active form of β-arrestin2
(Kovoor et al., 1999). Substitution mutants V54D and R170E showed significantly
increased interaction with PSD95 compared to wild-type β-arrestin2. Substitution
mutants K34Q, Q173L, and F174L showed no significant differences in interaction with
PSD95. Although substitution mutant A175F didn’t show a significant difference in coimmunoprecipitation with PSD95, there appeared to be a trend towards a decrease (Fig.
3.7B). This was confirmed when follow-up statistical testing with an unpaired two-tailed
t-test revealed that β-arrestin2 A175F significantly decreased interaction with PSD-95
compared to wild-type β-arrestin2 (Fig. 3.7C). This indicated residue A175 was
important for mediating β-arrestin2 interaction with PSD95.

3.3 Modifying arrestin-PDZ interactions impairs β-arrestin2
recruitment to CRFR1
It was previously demonstrated that while CRFR1 internalization was β-arrestindependent, multiple PDZ proteins could antagonize endocytosis (Dunn et al., 2016, 2013;
Hammad et al., 2015). This included PDZ protein PSD95, which was demonstrated to
antagonize β-arrestin2 recruitment to CRFR1 (Dunn et al., 2016). Therefore, our studies
looked to further explore whether PDZ interacts with β-arrestin2 contributed to the
regulation of β-arrestin2 recruitment to CRFR1. To do this we tested the previously
described β-arrestin2 mutants ability to interact with the CRFR1. We tested how CRF
agonist stimulation would affect both recruitment over time and the maximal response. It
was found that while mutants V54D, R170E, Q173L, and A175F decreased CRF-
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Modifying arrestin-PDZ interactions impairs agonist-stimulated β-

arrestin2 recruitment to CRFR1. (A) Bioluminescent Resonance Energy Transfer
(BRET) was employed to quantify the recruitment of β-arrestin2 as well as mutant forms
K34Q, V54D, and R170E to CRFR1. An initial BRET ratio was calculated followed by
various concentrations of CRF. BRET ratios are shown at 20 minutes post stimulation.
The data are representative of the mean ± SEM of 4 independent experiments. (B) BRET
readings correspond to the recruitment of β-arrestin2 as well as mutant forms K34Q,
V54D, and R170E to CRFR1. An initial BRET ratio was calculated followed by 500 nM
CRF stimulation. BRET ratios were repeatedly calculated following CRF stimulation and
plotted over time. The data are representative of the mean ± SEM of 4 independent
experiments. (C) BRET readings correspond to the recruitment of β-arrestin2 as well as
mutant forms Q173L, F174L, and A175F to CRFR1. An initial BRET ratio was
calculated followed by various concentrations of CRF. BRET ratios are shown at
20 minutes post stimulation. The data are representative of the mean ± SEM of 4
independent experiments. (D) BRET readings correspond to the recruitment of βarrestin2 as well as mutant forms Q173L, F174L, and A175F to CRFR1. An initial BRET
ratio was calculated followed by 500 nM CRF stimulation. BRET ratios were then
repeatedly calculated following CRF stimulation and plotted over time. The data are
representative of the mean ± SEM of 4 independent experiments.
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stimulated β-arrestin2 recruitment to HA-CRFR1 over time, mutants K43Q, and F174L
had similar levels of CRF-stimulated β-arrestin2 recruitment to HA-CRFR1 compared to
control (Figure 3.8 B and D). To further validate our findings, we assessed translocation
of these β-arrestin2 mutants in response to increasing concentrations of CRF under the
same conditions. We found that while mutants K43Q and F174L had a similar maximal
response for CRF-stimulated β-arrestin translocation compared to control, mutants V54D,
R170E, Q173L, and A175F reduced the maximal response for CRF-stimulated β-arrestin
translocation (Figure 3.8 A and C). Therefore, since β-arrestin2 substitution mutant
A175F was previously also shown to have impaired binding to PSD-95, perhaps the
decrease in recruitment to CRFR1 is due to impaired interaction with PDZ proteins.
To further validate the previously created β-arrestin2 mutants K34Q, Q173L,
F174L, and A175F, we recreated the mutants with different amino acid substitutions and
made sure any functional changes seen with the mutants couldn’t be attributed to
disruptions in protein folding. For mutant A175F, we also created substitutions with
glycine and leucine to make A175G and A175L. For mutants K34Q, Q173L, and F174L
we substituted all of them with alanine to create K34A, Q173A, and F174A. We then
tested how CRF agonist stimulation would affect both recruitment over time and maximal
response of all the new mutants. We found that mutants K34Q and K34A, as well as
F174L and F174A, showed no changes in CRF-stimulated β-arrestin2 recruitment to HACRFR1 over time and no changes in maximal response for CRF-stimulated β-arrestin
translocation compared to control (Fig 3.9 A, B, E, F). While mutant Q173A also showed
no changes in recruitment to HA-CRFR1 over time or maximal response, mutant Q173L
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seemed to decrease recruitment to HA-CRFR1 over time as well as the maximal response
(Fig 3.9 C, D). While mutant A175G also showed no changes in recruitment to HACRFR1 over time or maximal response, mutants A175L and A175F seemed to decrease
recruitment to HA-CRFR1 over time as well as the maximal response (Fig 3.9 G, H).
Therefore β-arrestin2 mutants A175F and A175L, but not A175G, show impaired
agonist-stimulated recruitment to CRFR1.
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Figure 3.9.

β-arrestin2 mutants A175F and A175L, but not A175G, show

impaired agonist-stimulated recruitment to CRFR1. (A and B) Bioluminescent
Resonance Energy Transfer (BRET) was employed to quantify the recruitment of βarrestin2 as well as mutant forms K34Q and K34A to CRFR1. The data are representative
of the mean ± SEM of 4 independent experiments. (C and D) BRET readings correspond
to the recruitment of β-arrestin2 as well as mutant forms Q173L and Q173A to CRFR1.
The data are representative of the mean ± SEM of 4 independent experiments. (E and F)
BRET readings correspond to the recruitment of β-arrestin2 as well as mutant forms
F174L and F174A to CRFR1. The data are representative of the mean ± SEM of 4
independent experiments. (G and H) BRET readings correspond to the recruitment of βarrestin2 as well as mutant forms A175G, A175L, and A175F to CRFR1. The data are
representative of the mean ± SEM of 4 independent experiments. (A, C, E, G) An initial
BRET ratio was calculated followed by various concentrations of CRF. (B, D, F, H) An
initial BRET ratio was calculated followed by 500 nM CRF stimulation. BRET ratios
were repeatedly calculated following CRF stimulation and plotted over time.
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Chapter 4: Discussion
GPCRs form an important family of proteins due to their widespread distribution
in the body and essential role in regulating many different physiological functions that
control homeostasis within the body. It is thus crucial to understand the signalling and
trafficking properties of each receptor, as well as the proteins responsible for regulating
these processes. Though much research has been dedicated to understanding GPCRs,
many questions have not yet fully been answered. Although the regulation of GPCR
trafficking properties by scaffolding proteins such as PDZ proteins and arrestins have
been widely documented, the complex relationship between the two protein families has
yet to be fully characterized. In addition, the mechanism of PDZ protein regulation for
GPCR trafficking properties is not fully understood. This project thus focuses on further
understanding how PDZ proteins regulate GPCR trafficking and whether it occurs
through interactions with β-arrestin2. This is of importance since a further
characterization of this interaction could lead to the development of novel
pharmacological targets. The first key finding of this study is that multiple PDZ domain
containing proteins are capable of interacting with β-arrestin2 via the PDZ domain.
Secondly, it was determined that β-arrestin2 substitution mutant A175F shows impaired
interaction with PDZ protein PSD-95, thus highlighting the importance of the residue in
mediating PDZ-arrestin interactions. Finally, it was found that modifying arrestin-PDZ
interactions impairs agonist-stimulated β-arrestin2 recruitment to CRFR1.

4.1 Association between PDZ proteins and β-arrestin2
This present thesis demonstrates the novel association of β-arrestin2 with PDZ
proteins PSD-95, MAGI1, and PDZK1. These interactions were confirmed through co47

immunoprecipitation experiments in HEK293 cells (Figure 3.1, 3.2, and 3.3). Since the
only shared protein interaction domain between all three PDZ proteins is the PDZ
domain, this suggested that PDZ-arrestin interactions are mediated through the PDZ
domain. This was further confirmed with our next experiment that looked at the
interaction between β-arrestin2 and the four PDZ domains of PDZK1 (Figure 3.4). We
demonstrated that only the first PDZ domain of PDZK1 interacts with β-arrestin2 and
thus may be important for mediating the interaction. Furthermore, at least for PDZK1,
this implies that the interaction occurs through a single domain and not multiple domains.
Taken together, these findings provide new functional significance for the interactions
between β-arrestin proteins and PDZ proteins. It has recently been shown that the
Endothelin A receptor (ETAR) regulates formation of invadopodia in cancer cells through
RhoC activity, which in turn is regulated by a direct interaction between β-arrestin1 and
PDZ domain containing protein PDZ-RhoGEF (Bagnato & Rosanò, 2016; Semprucci et
al., 2016). However, the mechanism of interaction remains unclear and it remains to be
determined what role the PDZ domain plays in mediating this interaction (Bagnato &
Rosanò, 2016; Semprucci et al., 2016). Nevertheless, this provides further evidence for
direct PDZ protein interactions with β-arrestins.
Beyond the bounds of this current thesis, we would like to further characterize
these novel interactions. Although it now seems likely that arrestin-PDZ interactions are
mediated through the PDZ domain, future experiments could look at which amino acids
or motifs within PDZ domains meditate this interaction. Of particular interest would be to
determine the involvement of the GLGF motif present in PDZ domains. This motif has
previously shown to facilitate hydrogen bond formation and binding of many ligands to
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PDZ domains (Kalyoncu et al., 2010; Sheng & Sala, 2001). Another future means of
characterizing arrestin-PDZ interactions would be to confirm whether this is a direct or
indirect interaction. Since co-immunoprecipitation experiments can reveal both direct and
indirect interactions, it is still possible that the interaction is in fact mediated through
bridging proteins. Future experiments could use techniques such as GST-pull downs or
FRET to confirm a direct interaction (Phizicky & Fields, 1995; Rao et al., 2014). Finally,
it would be interesting to replicate these co-immunoprecipitation experiments in mouse
brain tissue and test if these interactions can also take place with endogenously expressed
proteins in physiologically relevant tissue.

4.2 Mechanism of interaction between PDZ proteins and βarrestin2
It has previously been found that though Vps26A shows low sequence homology
with the arrestin family, there is a high degree of structural similarity with arrestin
proteins (Shi et al., 2006). We showed that, of all arrestin family members, β-arrestin2
showed the highest degree of structural similarity with Vps26A (Table 3.1 & Figure 3.5).
This structural similarity is of importance because Vps26A has also been shown to
interact with the PDZ domain of SNX27 (Gallon et al., 2014). Since Vps26A binds to the
PDZ domain of SNX27, and is closely structurally aligned with β-arrestin2, we
hypothesized that perhaps β-arrestin2 interacts with PDZ domain containing proteins in a
similar manner. We tested this, by using its structural similarities to Vps26A, to create
several point mutations in β-arrestin2 (Table 3.2 and Figure 3.6). We tested the ability of
these mutants to bind PDZ proteins by comparing levels of co-immunoprecipitation with
PSD-95 (Fig. 3.7). While mutants V54D and R170E immunoprecipitated with PSD-95 at
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higher amounts compared to wild type β-arrestin2, A175F showed decreased interaction
with PSD-95. This alanine residue at position 175 in bovine β-arrestin-2 is conserved in
multiple other species as well as in Vps26A, thus indicating its potential importance.
Gallon et al., (2014) describe that the structurally analogous residue of A175 in Vps26A,
A155, is in L10 and involved in main chain contacts through stretches of intermolecular
β-sheets with residues 65–66 preceding the β3-β4 hairpin within the SNX27 PDZ
domain. This residue is part of Vps26A’s short linker region that connects the two
domains of Vps26A, the N-terminal domain (N domain) and C-terminal domain (C
domain). This interdomain linker consists of a 15-residue loop, from 149 to 163, and has
been found to be flexible as well as relatively mobile (Gallon et al., 2014; Shi et al.,
2006). It has been determined that in visual arrestin this region is at position 179 to 191
Vishnivetskiy et al., 2002). This corresponds with amino acids from position 173 to 185
in β-arrestin2, and it contains A175. Since β-arrestin2 A175F did not completely abolish
interaction with PSD-95, perhaps it is part of several amino acids in this region important
for mediating interactions with PDZ proteins. It would be interesting in future studies to
create double and triple amino acid mutant forms of β-arrestin2 and observe how that
would effect PDZ protein binding.
Although β-arrestin2 does not contain a canonical PDZ binding motif, it is
possible it contains an internal PDZ binding motif. Evidence suggests that some PDZ
domains may bind to internal PDZ binding motifs contained within target proteins (Harris
& Lim, 2001; Trejo, 2005). Though the sequence of the internal PDZ binding motifs
remains to be determined, it has been shown that many of them possess a sharp β-turn
similar in structure to canonical motifs often found on the C-terminals of ligands
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(Paasche et al., 2005). Therefore, further experiments are needed to determine if βarrestin uses an internal PDZ binding motif to bind PDZ domains.

4.3 Role of arrestin-PDZ interactions in β-arrestin2 recruitment
to CRFR1
Due to the potential role of arrestin-PDZ interactions in mediating PDZ protein
regulation of GPCR trafficking, we next moved on to explore the effects of arrestin-PDZ
interactions on β-arrestin2 recruitment to CRFR1. We also wanted to further characterize
the previously created β-arrestin2 substitution mutants and how they would affect
arrestin-PDZ interactions. β-arrestin2 mutants K34Q and F174L showed no change in
CRF-stimulated β-arrestin2 recruitment to CRFR1 and no change in the maximal
response for CRF-stimulated β-arrestin translocation (Figure 3.8). However, mutants
V54D, R170E, Q173L, and A175F all showed a decrease in both CRF-stimulated βarrestin2 recruitment to CRFR1 and maximal response for CRF-stimulated β-arrestin
translocation (Figure 3.8). Therefore these residues may be important for β-arrestin2
recruitment to CRFR1. Combined with data that shows decreased interaction of PSD-95
with β-arrestin2 A175F (Figure 3.7), it implicates that residue A175, perhaps in
combination with other nearby amino acids, might be integral for association of βarrestin2 with PDZ proteins and thereby modulates β-arrestin2 recruitment and GPCR
endocytosis.
To further investigate the β-arrestin2 mutants K34Q, Q173L, F174L, and A175F,
we recreated additional mutants with different amino acid substitutions (Figure 3.9).
While mutant A175G showed no changes in its recruitment to CRFR1, mutants A175L
and A175F both showed decreased recruitment to CRFR1. A similar recruitment level to
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CRFR1 between A175L and A175F verifies that any functional changes seen with mutant
A175F are due to change in amino acid and not disruption of the protein backbone of βarrestin-2. It is possible that no change in recruitment was seen with A175G because
glycine is much smaller and closer to alanine, and therefore wasn’t a big enough change
from alanine to show any changes in arrestin recruitment. Alanine screening of residues
K34 and F174 show no differences in β-arrestin2 recruitment to CRFR1, thus further
confirming the validity mutants K34Q and F174L. However, while mutant Q173L
showed decreased recruitment to CRFR1, Q173A showed no changes in recruitment to
CRFR1. It is possible substituting the polar glutamine for a hydrophobic leucine
somehow disrupted regular function of β-arrestin2, however further studies are needed.
It has previously been proposed that activation and binding of arrestin to GPCRs
induces a conformation change in arrestin and movement of the N- and C- terminals
(Gurevich and Gurevich 2004). These conformational rearrangements suggest that
arrestin binds the receptor from the concave domains, while the convex side of arrestin is
left to bind other various binding partners may that regulate trafficking and downstream
signalling of GPCRs (Lohse & Hoffmann, 2014). In addition to inter-domain
rearrangements, multiple movements in the arrestin loops have also been detected that are
in part responsible for activation of arrestin and binding to the receptor (Shukla et al.
2013). The hinge loop that connects the N- and C- extremities of arrestin has been shown
to be necessary for maintaining receptor/arrestin complexes in a stable conformation
(Vishnivetskiy et al. 2002). This was shown when sequential deletion in the hinge region
of visual arrestin resulted in a decreased ability to bind rhodopsin (Vishnivetskiy et al.
2002). While some studies propose arrestins change conformation in a “clamshell”-like
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manner to wrap around the receptors (Gurevich and Gurevich 2004), in contrast, more
recent studies suggest that the N- and C- terminal domains of the activated arrestin
undergo a 20° rotation from the central axis and this twisting facilitates interaction with
the receptor (Fig 4.1 and Fig 4.2) (Shukla et al. 2013). Either way, it seems flexibility and
movement of the two domains is required for interaction with the receptor. Therefore, it
is possible that binding of PDZ proteins in the flexible linker region may sterically inhibit
any spatial movements or changes in conformation of β-arrestin. This also may serve to
prevent β-arrestin interaction with GPCRs, and thereby receptor internalization (Fig 4.2C
and D). This would also provide an alternative explanation for why mutant A175G shows
no changes in recruitment to CRFR1 compared to mutants A175L and A175F. Glycine,
though small and similar to alanine, is unusually flexible and allows for changes in
conformation generally not allowed by other amino acids. Therefore, it is possible
changing alanine to glycine didn’t prevent the conformational changes in β-arrestin that
changing to leucine or phenylalanine did.
Alternatively, other than conformational changes, it is also possible that binding
of PDZ proteins to β-arrestins dictates the stability of the receptor–β-arrestin complex.
GPCRs exhibit different patterns of agonist-induced β-arrestin interactions where, while
some receptors form stable complexes with β-arrestin and internalize as a unit to
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Figure 4.1

Conformational changes associated activation of β-arrestin-1.

(A) Shows the structural features of the finger, middle and lariat loops of the inactive
(grey) form of arrestin and the conformational rearrangements associated to its active
form (orange). (B) Representation of the 20° rotational movement of the arrestin when
switching from an inactive (grey) to active (orange) form. (C) View of arrestin movement
from the C-terminal domain (Modified from Shukla et al., 2013).
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Figure 4.2

Proposed schematic of how PDZ protein and β-arrestin interactions

regulate GPCR endocytosis. (A) β-arrestin does not bind GPCRs at the plasma
membrane in its basal inactive conformation. (B) When switching to an active
conformation, β-arrestin undergoes a 20° rotation along its central axis which allows it to
bind GPCRs and cause receptor internalization. (C) It is possible that binding of PDZ
proteins to β-arrestin prevents any spatial movements or changes in the conformation of
β-arrestin such that it can no longer bind GPCRs. (D) It is thus possible that upon binding
to GPCDs, PDZ proteins prevent GPCR endocytosis, through binding of β-arrestins and
preventing their interaction with GPCRs.
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endosomes, others bind β-arrestin transiently and dissociate after internalization of the
receptor recycle back to the plasma membrane (Oakley et al., 2000; Zhang et al., 1999).
The stability of the receptor–β-arrestin interaction might dictate the fate of the
internalized receptor. Receptors that transiently bind β-arrestin seem to be more likely to
recycle back to the plasma membrane whereas receptors that form stable interactions with
β-arrestin seem to be more likely to be targeted to the lysosome for degradation (Luttrell
& Lefkowitz, 2002). It is possible PDZ protein binding to β-arrestins regulates stability of
the receptor–β-arrestin complex to modulate receptor recycling and degradation.
For future studies, it will be important to fully explore the how PDZ proteins and
β-arrestins interact to regulate β-arrestin recruitment and receptor trafficking. There have
been conflicting results as to what effect PDZ protein/β-arrestin interactions have on βarrestin recruitment to receptors. PSD-95 has been shown to antagonize the recruitment
of β-arrestin2 to GPCRs CRFR1, β1AR, and 5-HT2AR (Dunn et al., 2016; Hu et al., 2000;
Xia et al., 2003). However, PDZ proteins may also facilitate the recruitment of βarrestins to the receptor as has previously been demonstrated with PDZ protein NHERF1
interactions with CC chemokine receptor 5 (Hammad et al., 2010). This may be
explained by receptor-specific functions or even variances due to cell-specific roles. It
would be interesting in future studies to look at how the β-arrestin2 mutants affect
recruitment to GPCRs other than CRFR1. Additionally, future experiments could use
flow cytometry to look at how all the β-arrestin2 mutants affect agonist stimulated
receptor endocytosis. Overall, further studies are required to better understand the
relationship between these two important regulators of receptor trafficking.
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4.4 Summary
This thesis elucidates the novel association between β-arrestin and PDZ domain
containing proteins. More specifically, this interaction occurs via PDZ domains and
regulates trafficking properties for GPCRs, including CRFR1, through modulation of βarrestin2 recruitment. Pharmacologically targeting the interactions between β-Arrestin2
and the PDZ proteins could lead to specific regulation strategies for the numerous
disorders associated with congenital or acquired disregulation of GPCR signaling. Rather
than modulating neurotransmitter availability, we can begin to not only target specific
receptors activated by these neurotransmitters, but also modulate specific signalling
pathways or receptor trafficking processes that underlie a spectrum of mental illnesses
including, though not limited to, anxiety, depression, and schizophrenia.
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